Skip to content
Tuesday 25 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,886.16
+0.29%
DAX
26,266.14
+0.61%
CAC 40
8,439.20
-0.16%
STOXX 50
6,455.63
+0.12%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Saturday 14 May 2016 3:34 pm

Pfizer bans its drugs from use in lethal injections

By: James Nickerson

Add as a preferred source on Google

Pfizer has become the latest pharmaceutical company to ban its drugs from use in lethal injections.

The company is the last major drugs maker to ban its drugs in the use of capital punishment, meaning the open market for drugs is closed to states which still execute people.

The decision has called into question the viability of the death penalty in some American states.

Read more: Morning Wire Unregulated: Episode 1 – Panama Papers, Pfizer and Allergan

"Pfizer makes its products to enhance and save the lives of the patients we serve. Consistent with these values, Pfizer strongly objects to the use of its products as lethal injections for capital punishment," the pharma giant said.

The company will only sale to wholesalers who sign contracts that commits them not to sell them to state authorities for the use of executions.

All 25 drug companies approved by the US Food and Drug Administration have blocked their products in capital punishment, says human rights group Repreive.

"Pfizer's actions cement the pharmaceutical industry's opposition to the misuse of medicines," Maya Foa, its director, said

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Trending Articles

  • Andy Burnham hints at tax rises in Autumn Budget

  • Can debt-ridden Morrisons become a Big Four supermarket again?

  • Budget 2026: Which taxes will Burnham and Healey hike?

  • As it happened: Stocks rally; US to unveil ‘economic D-Day’ Iran sanctions

  • As it happened: FTSE 100 jumps in best streak since May; Vistry, Melrose lead risers

More from Morning Wire

  • Tour de France Femmes: World famous cycling race plunged into bra row

    Sport Business
    Tour de France Femmes avec Zwift banners promoting the Grand Départ in Great Britain 2027
  • Cycle Pharmaceuticals Selects Forma Life Sciences to Establish U.S. Commercial Supply for FDA-Approved CAVHANZA™ (nilotinib) Orally Disintegrating Tablets

    Business Wire
  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • Astrazeneca share price tumbles on $400bn megamerger talks

    Investing
    Astrazeneca headquarters with logo, reflecting commitment to reduce US medicine prices after Trump administration pressure
  • Cleansed is still the most harrowing play you’ll ever see

    Life&Style
    A man and woman in an intimate embrace, surrounded by a field of orange and yellow flowers on a dark stage
  • ‘Absurd’: Government seeks quantum tech chief – no experience necessary

    Tech
    Advanced quantum computer with intricate circuits and glowing interface, illustrating cutting-edge technology innovations
  • Death Note: The Musical review – a high-shine, high school take on the trolley problem

    Life&Style
    Xander Pang Light and the cast of Death Note The Musical on stage with Tokyo cityscape projections
  • In Jason Arday, Cambridge is discovering the dangers of DEI

    Opinion
    Jason Arday smiling, wearing academic regalia with a blue cap and gown with red accents.
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook